GLP-1 Receptor Agonists in Alzheimer’s Disease: Emerging Off-Label Neuroprotective Potential

https://www.news-medical.net/health/GLP-1-receptor-agonists-in-Alzheimere28099s-disease-Emerging-off-label-neuroprotective-potential.aspx From reduced amyloid and neuroinflammation in experimental models to mixed cognitive outcomes in clinical trials, emerging evidence is testing whether GLP-1 receptor agonists can move beyond metabolic therapy to become meaningful treatments for Alzheimer’s disease. Type 2 diabetes (T2D) and insulin resistance are associated with an increased risk of cognitive decline and dementia, including Alzheimer’s disease (AD). This association has led researchers to investigate the therapeutic potential of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as semaglutide, for reducing dementia risk or slowing cognitive decline; however, a direct disease-modifying benefit in established AD remains unproven.4,5 GLP-1 RAs are approved for metabolic indications such as T2D and obesity rather than AD, so use specifically to prevent or treat AD remains off-label and investigational.3,4